Proceedings: AACR Annual Meeting 2021; April 10-15 and May 17-21
Introduction: Based on molecular classification of endometrial cancer (EC) of The Cancer Genome Atlas (TCGA) and Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), EC has been classified into four novel prognostic groups: POLE-mutated (POLE-mt), mismatch repair-deficient (dMMR), copy number-high (p53abn), and copy number-low (no specific molecular profile, NSMP). We hypothesized that spatial distribution of tumor-infiltrating lymphocyte (TIL) using an artificial-intelligence (AI)-powered tissue analyzer, Lunit SCOPE, would be distinct according to the molecular classification.
Methods: We analyzed EC of TCGA database (N=224) and EC tissues retrospectively collected from Seoul National University Bundang Hospital (SNUBH, N=236). EC from SHUBH were molecularly classified in which MMR and p53 status were determined by immunohistochemistry (IHC) and POLE mutation by digital droplet polymerase chain reaction of six hotspot mutations in exon 9, 13 and 14 (P286R, S297F, V411L, V424I, L424V, and A456P). Lunit SCOPE analysis to detect lymphocyte, cancer epithelium (CE), and cancer-associated stroma (CS) was performed using x40 scanned images of TCGA and SNUBH. Cox proportional hazard model were used for survival analysis.
Results: Composition of molecular classification were comparable in both cohorts: 7.6%, 28.6%, 24.6%, and 39.3% for POLE-mt, dMMR, CN-high, and CN-low in TCGA cohort, and 8.9%, 19.5%, 17.4%, and 54.2% for POLE-mt, dMMR, p53abn, and NSMP in SNUBH cohort, respectively. CN-high subtype in TCGA and p53abn in SNUBH cohort significantly correlated with poor prognosis (TCGA: adjusted hazard ratio 2.54, p value 0.0383; SNUBH: adjusted hazard ratio 7.47, p value 2.38 x 10-4). TIL density calculated by total number of lymphocytes in CE and CS area was significantly increased in POLE and MSI groups of TCGA-cohort (p value = 2.24 x 10-4) and SNUBH-cohort (p value = 1.74 x 10-6). Moreover, uneven TIL enrichment in CS was observed in CN-high or TP53-expressor compared to CN-low or TP53-wildtype (ratio of TIL in CS / TIL in CE, TCGA: 6.96 versus 5.33; SNUBH: 11.4 versus 8.83). These findings suggested that the CN-high/p53abn and POLE/dMMR subtypes might be associated with immune-excluded and immune-inflamed tumor microenvironment (TME) phenotype, respectively.
Conclusion:The distribution of TIL in EC differs according to the molecular subtypes. Our data suggest the possibility of predicting subtypes through TIL analysis, and provide insight into treatment through TME modulation.
Hyojin Kim, Eun Sun Kim, Song Kook Lee, Jeong Hoon Lee, Kyunghyun Paeng, Chan-Young Ock, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong-Beom Kim.
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of, Lunit Inc., Seoul, Korea, Republic of, Lunit Inc, Seoul, Korea, Republic of, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Abstract: Deep learning-based predictive biomarker for adjuvant chemotherapy in early-stage hormone receptor-positive breast cancer
Abstract: Pan-cancer analysis of tumor microenvironment using deep learning-based cancer stroma and immune profiling in H&E images
Abstract: Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer
Abstract: Comprehensive deep learning analysis of H&E tissue phenomics reveals distinct immune landscape and transcriptomic enrichment profile among immune inflamed, excluded and desert subtypes...
Abstract: Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor...
Abstract: Deep learning-based immune phenotype analysis reveals distinct resistance pattern of immune checkpoint inhibitor in non-small cell lung cancer
Reducing Domain Gap by Reducing Style Bias
Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge
Accuracy and efficiency of an artificial intelligence tool when counting breast mitoses
Abstract: Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes (TIL) to reflect target gene expressions of novel immuno-oncology agents.
Abstract: Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by ...
Abstract : Pathologic validation of artificial intelligence-powered prediction of combined positive score of PD-L1 immunohistochemistry in urothelial carcinoma.
Abstract : Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) ...
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
Abstract : Deep learning based radiomic biomarker for predicting the presence of high-grade histologic patterns in lung adenocarcinoma
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals distinct genomic profile of immune excluded phenotype in pan-carcinoma
Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
Using artificial intelligence to read chest radiographs for tuberculosis detection: A multi-site evaluation of the diagnostic accuracy of three deep learning systems
Abstract : Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Abstract : Assistance with an artificial intelligence-powered PD-L1 analyzer reduces interobserver variation in pathologic reading of tumor proportion score in non-small cell lung cancer
Abstract : AI-powered whole-slide image analysis of tumor-infiltrating lymphocytes for prediction of prognosis in colorectal cancer
Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Artificial Intelligence–Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Non–Small-Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Analyzer Reduces Inter-observer Variation in PD-L1 Tumor Proportion Score of Non-Small Cell Lung Cancer
Abstract : Artificial Intelligence-Powered Tumor Purity Assessment From H&E Whole Slide Images Correlates...
Abstract : Deep learning-based H&E analyzer reveals distinct immune profiles and clinical outcomes among immune phenotypes in uterine corpus endometrial carcinoma
Abstract : Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals immune-excluded phenotype is correlated with TGF-beta pathway related genomic aberrations
Observer Performance Study to Examine the Feasibility of the AI-powered PD-L1 Analyzer to Assist Pathologists’ Assessment of PD-L1 Expression Using Tumor Proportion Score in Non-Small Cell Lung Cancer
Artificial intelligence-powered human epidermal growth factor receptor 2 (HER2) analyzer in breast cancer as an assistance tool for pathologists to reduce interobserver variation
Artificial intelligence-powered whole-slide image analyzer reveals a distinctive distribution of tumor-infiltrating lymphocytes in neuroendocrine tumors and carcinomas
Artificial Intelligence (AI) - powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple negative breast cancer (TNBC)
Artificial intelligence (AI)-powered pathology image analysis merged with spatial transcriptomics reveals distinct TIGIT expression in the immune-excluded tumor-infiltrating lymphocytes
Trastuzumab plus FOLFOX for Gemcitabine/Cisplatin refractory HER2-positive biliary tract cancer: a multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)
The Inflamed Immune Phenotype (IIP): a clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types
Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: a phase I study
Robust artificial intelligence-powered imaging biomarker based on mammography for risk prediction of breast cancer.